Anticancer Drugs Durvalumab Oncology Pharmacology Physiotherapy

Durvalumab (Warnings-1)

In this article we will discuss Durvalumab (Warnings-1)

In this article, we will discuss Durvalumab (Warnings-1). So, let’s get started.

Immune-Mediated Adverse Reactions

Durvalumab is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death-receptor 1 (PD-1) or the PD-ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.